Efficacy of vaccine Oncophage application in patients with renal cancer
https://doi.org/10.17650/1726-9776-2008-4-4-17-21
Abstract
Renal cancer is one of the most severe oncourologic diseases. In 2005, 15,733 new cases were registered in the Russian Federation. Total life expectancy of patients with advanced form of the disease is around one year unless patients respond to treatment with available late stage therapeutic agents. Therefore, delaying or preventing disease recurrence in patients with early-stage disease is critical. Oncophage was evaluated as an adjuvant treatment after nephrectomy in patients with high relapse risk in a randomized, multicenter, international Phase III study. At the moment Oncophage can be regarded as effective treatment in the adjuvant setting in the management of renal cancer patients with intermediate prognosis after radical nephrectomy.
About the Authors
O. B. Karyakin
State Enterprise Medical Radiological Research Centre of Russian Academy of Medical Sciences
Russian Federation
Obninsk
Russian Federation
Obninsk
A. M. Popov
State Enterprise Medical Radiological Research Centre of Russian Academy of Medical Sciences
Russian Federation
Obninsk
Russian Federation
Obninsk
References
1. Чиссов В.И., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2005 году (заболеваемость и смертность). М., 2007.
2. Tsui K.H., Shvarts O., Smith R.B. et al. Prognostic indicators for renal cell carcinoma: a multivariate analysis of 643 patients using the revised 1997 TNM staging criteria. J Urol 2000; 163: 1090—5.
3. Pizzocaro G., Piva L., Colavita M. et al. Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study. J Clin Oncol 2001;19:425—31.
4. Giuliani L., Giberti C., Martorana G., Rovida S. Radical extensive surgery for renal cell carcinoma: long-term results and prognostic factors. J Urol 1990;143: 468—73.
5. Messing E.M., Manola J., Wilding G. et al. Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. J Clin Oncol 2003;21:1214—22.
6. Negrier S., Perol D. et al. Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal cell carcinoma of intermediate prognosis: results of a randomized controlled trial. Cancer 2007;110(11):2468—77.
7. Kim H.L., Seligson D., Liu X. et al. Using protein expressions to predict survival in clear cell renal carcinoma. Clin Cancer Res 2004;10(16):5464—71.
8. Kunkle D.A., Crispen P.L., Li T., Uzzo R.G. Tumor size predicts synchronous metastatic renal cell carcinoma: implications for surveillance of small renal masses. J Urol 2007;177:1692—6.
9. Zisman A., Pantuck A.J., Wieder J. et al. Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol 2002;20:4559—66.
10. Shvarts O., Lam J.S., Kim H.L., Belldegrun A.S. Staging of renal cell carcinoma: current concepts. BJU Int 2005;95(suppl 2):8—13.
11. Frank I., Blute M.L., Cheville J.C. et al. A multifactorial postoperative surveillance model for patients with surgically treated clear cell renal cell carcinoma. J Urol 2003;170:2225—32.
12. Zisman A., Pantuck A.J., Dorey F. et al. Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol 2001;19:1649—57.
13. Kattan M.W., Reuter V., Motzer R.J. et al. A postoperative prognostic nomogram for renal cell carcinoma. J Urol 2001;166:63—7.
14. Galfano A., Novara G., Iafrate M. et al. Mathematical models for prognostic prediction in patients with renal cell carcinoma. Urol Int 2008;80(2):113—23.
15. Fyfe G., Fisher R.I., Rosenberg S.A. et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995;13(3):688—96.
16. MRCRC Collaborators. Interferonalpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Lancet 1999;353:14—7.
17. McDermott D.F., Regan M.M., Clark J.I. et al. Randomized phase III trial of high-dose interleukin-2 vs subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005;23:133—41.
18. Pyrhonen S., Salminen E., Ruutu M. et al. Prospective randomized trial of interferon alfa-2a plus vinblastine vs vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 1999;17:2859—67.
19. Yang J.C., Sherry R.M., Steinberg S.M. et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 2003;21:3127—32.
20. Escudier B., Eisen T., Stadler W.M. et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125—34.
21. Motzer R.J., Hutson T.E., Pharm D. et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356(2):115—24.
22. Haas N. Update on targeted therapy adjuvant trials (ECOG/MRC). 5th International Symposium of the Kidney Cancer Association. Chicago, IL, USA; Sept 22-23, 2006.
23. Jocham D., Richter A., Homann L. et al. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet 2004;363:594—9.
24. Doehn C., Richter A., Theodor R. et al. Prolongation of progression-free and overall survival following an adjuvant vaccination with Reniale in patients with nonmetastatic renal cell carcinoma: secondary analysis of a multicenter phase-III trial. Onkologie 2006;29(3 suppl):58.
25. Holtl L., Zelle-Rieser C., Gander H. et al. Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells. Clin Cancer Res 2002;8:3369—76.
26. Galligioni E., Quaia M., Merlo A. et al. Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and bacillus Calmette-Guerin: Five-year results of a prospective randomized study. Cancer 1996;77:2560—6.
27. Wood C., Srivastava P., Bukowski R. et al. An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial. Lancet 2008;372(9633):145—54.
28. Srivastava P. Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses. Annu Rev Immunol 2002;20:395—425.
29. Suto R., Srivastava P.K. A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides. Science 1995;269:1585—8.
30. Jonasch E., Wood C., Tamboli P. et al. Vaccination of renal cell carcinoma patients with autologous tumor-derived vitespen vaccine: clinical findings. Br J Cancer 2008;98(8):1336—41.
31. Motzer R.J., Mazumdar M., Bacik J. et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999;17: 2530—40.
32. Joint Committee on Cancer. Kidney cancer. In: Greene FL, Page DL, Fleming ID, et al, eds. AJCC cancer staging manual, 6th edn. New York: Springer, 2002: 323—25.
Review
For citations:
Karyakin O.B., Popov A.M. Efficacy of vaccine Oncophage application in patients with renal cancer. Cancer Urology. 2008;4(4):17-20. (In Russ.) https://doi.org/10.17650/1726-9776-2008-4-4-17-21
Views:
297
Email this article 